See more : Pharma Mar, S.A. (PHM.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Heron Therapeutics, Inc. (HRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Varca Ventures, Inc. (VRCV) Income Statement Analysis – Financial Results
- Airthings ASA (AIRX.OL) Income Statement Analysis – Financial Results
- Snowline Gold Corp. (SGD.CN) Income Statement Analysis – Financial Results
- Allegro.eu SA (ALE.WA) Income Statement Analysis – Financial Results
- Valeo SE (VLEEF) Income Statement Analysis – Financial Results
Heron Therapeutics, Inc. (HRTX)
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.82M | 4.39M | 3.37M | 20.40M | 20.00M | 18.30M | 18.70M | 16.10M | 15.90M | 19.90M | 7.30M | 2.80M | 2.40M | 2.80M | 2.50M | 1.70M |
| Cost of Revenue | 65.11M | 54.87M | 46.02M | 36.19M | 61.62M | 27.51M | 4.59M | 35.00K | 734.00K | 54.83M | 30.92M | 14.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 445.00K | 440.27K | 613.20K | 6.40M | 5.70M | 6.00M | 9.40M | 9.80M | 9.00M | 11.60M | 3.80M | 1.10M | 1.20M | 700.00K | 600.00K | 400.00K |
| Gross Profit | 61.94M | 52.80M | 40.33M | 52.45M | 84.35M | 49.96M | 26.18M | 1.24M | -734.00K | -54.83M | -30.92M | -14.08M | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.37M | 3.95M | 2.75M | 14.00M | 14.30M | 12.30M | 9.30M | 6.30M | 6.90M | 8.30M | 3.50M | 1.70M | 1.20M | 2.10M | 1.90M | 1.30M |
| Gross Profit Ratio | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 92.35% | 89.96% | 81.78% | 68.63% | 71.50% | 67.21% | 49.73% | 39.13% | 43.40% | 41.71% | 47.95% | 60.71% | 50.00% | 75.00% | 76.00% | 76.47% |
| Research & Development | 55.90M | 107.51M | 130.82M | 174.53M | 167.38M | 140.03M | 138.58M | 103.13M | 61.18M | 54.83M | 32.78M | 15.05M | 8.21M | 7.26M | 7.80M | 19.51M | 19.36M | 15.24M | 10.30M | 11.50M | 8.66M | 6.70M | 7.35M | 3.71M | 4.30M | 4.40M | 3.70M | 3.50M | 4.10M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 49.01M | 37.44M | 40.15M | 42.23M | 37.90M | 29.26M | 25.55M | 21.37M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 67.64M | 82.51M | 87.18M | 63.85M | 89.76M | 64.60M | 56.60M | 47.67M | 17.35M | 8.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.66M | 119.95M | 127.33M | 106.08M | 127.66M | 93.87M | 82.16M | 69.03M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 8.50M | 17.50M | 8.80M | 4.90M | 5.10M | 6.70M | 6.90M | 4.50M |
| Other Expenses | 0.00 | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -38.00K | -2.23M | -666.00K | -1.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| Operating Expenses | 172.55M | 227.46M | 258.15M | 280.61M | 295.04M | 233.90M | 220.74M | 172.16M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.19M | 10.65M | 7.06M | 11.30M | 11.80M | 12.30M | 16.30M | 14.90M | 15.90M | 18.70M | 9.90M | 5.70M | 5.90M | 7.40M | 7.80M | 5.40M |
| Cost & Expenses | 237.66M | 282.33M | 304.17M | 316.80M | 356.66M | 261.41M | 225.33M | 172.19M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.64M | 11.09M | 7.67M | 17.70M | 17.50M | 18.30M | 25.70M | 24.70M | 24.90M | 30.30M | 13.70M | 6.80M | 7.10M | 8.10M | 8.40M | 5.80M |
| Interest Income | 3.36M | 1.64M | 433.00K | 3.63M | 7.26M | 5.97M | 1.05M | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 587.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.87M | 2.47M | 2.41M | 1.90M | 1.47M | 2.67M | 3.94M | 2.66M | 958.00K | 887.00K | 826.00K | 599.00K | 373.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.90M | 2.89M | 3.02M | 2.85M | 2.04M | 1.51M | 1.53M | 1.10M | 734.00K | 578.00K | 333.00K | 197.00K | 179.00K | 227.00K | 356.00K | 412.00K | 289.00K | -244.00K | 446.00K | 314.00K | 460.00K | 482.00K | 406.06K | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| EBITDA | -103.79M | -176.66M | -215.25M | -222.53M | -201.23M | -174.66M | -192.02M | -169.38M | -96.19M | -73.98M | -54.46M | -23.83M | -10.88M | -6.97M | -9.86M | -22.51M | -19.44M | 5.91M | -8.03M | -9.02M | -5.96M | -4.58M | -6.77M | -4.03M | -1.50M | -2.00M | -800.00K | -7.10M | -7.40M | -7.90M | -9.20M | -5.30M | -3.20M | -3.90M | -4.60M | -5.00M | -3.20M |
| EBITDA Ratio | -81.70% | -162.21% | -252.27% | -257.41% | -142.94% | -237.42% | -624.10% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,684.67% | -956.73% | -783.58% | -6,223.85% | -6,274.51% | 0.00% | -148.95% | -166.99% | -130.05% | -75.84% | -145.49% | -132.20% | 15.69% | 18.50% | 4.92% | -24.06% | -44.72% | -47.80% | -50.75% | -83.56% | -128.57% | -204.17% | -196.43% | -244.00% | -217.65% |
| Operating Income | -110.62M | -174.66M | -217.83M | -228.16M | -210.69M | -183.94M | -194.56M | -170.92M | -96.93M | -74.56M | -54.46M | -23.83M | -11.06M | -9.93M | -10.24M | -23.45M | -23.63M | -18.86M | -8.47M | -9.32M | -6.61M | -4.82M | -6.70M | -4.31M | 2.70M | 2.50M | -300.00K | -7.00M | -8.60M | -9.00M | -10.40M | -6.40M | -4.00M | -4.70M | -5.30M | -5.90M | -4.10M |
| Operating Income Ratio | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,712.38% | -763.57% | -812.21% | -6,353.66% | -5,736.17% | 0.00% | -157.17% | -172.39% | -136.39% | -82.96% | -152.79% | -127.96% | 13.24% | 12.50% | -1.64% | -37.43% | -53.42% | -56.60% | -52.26% | -87.67% | -142.86% | -195.83% | -189.29% | -236.00% | -241.18% |
| Total Other Income/Expenses | 56.00K | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -2.93M | -2.23M | -666.00K | -1.81M | -826.00K | -599.00K | -373.00K | 2.74M | 24.00K | 520.00K | 3.83M | 24.38M | 290.00K | 224.00K | 153.00K | 297.00K | 712.64K | 26.39K | 0.00 | 200.00K | 300.00K | 400.00K | -200.00K | -300.00K | 900.00K | 600.00K | 0.00 | 1.00M | 900.00K | 1.10M | 500.00K |
| Income Before Tax | -110.56M | -182.02M | -220.68M | -227.28M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -24.43M | -11.44M | -7.20M | -10.15M | -23.13M | -19.80M | 5.52M | -8.47M | -9.29M | -6.46M | -4.76M | -6.62M | -4.28M | 0.00 | 2.70M | 0.00 | -8.10M | -8.80M | -9.30M | -9.50M | -5.80M | -4.00M | -3.70M | -4.40M | -4.80M | -3.60M |
| Income Before Tax Ratio | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,770.12% | -553.11% | -804.92% | -6,266.94% | -4,805.83% | 0.00% | -157.11% | -171.98% | -133.23% | -81.79% | -150.83% | -127.18% | 0.00% | 13.50% | 0.00% | -43.32% | -54.66% | -58.49% | -47.74% | -79.45% | -142.86% | -154.17% | -157.14% | -192.00% | -211.76% |
| Income Tax Expense | 0.00 | -47.51M | -3.02M | -2.85M | 1.87M | 7.77M | 3.90M | -1.10M | -734.00K | -578.00K | -333.00K | -1.28M | 379.00K | -2.59M | -122.00K | -320.00K | 41.00K | 119.00K | -263.00K | -95.00K | -2.25M | -1.05M | -4.19M | -12.86M | 300.00K | 600.00K | 700.00K | 2.40M | 800.00K | 800.00K | -500.00K | -200.00K | 300.00K | -800.00K | -800.00K | -900.00K | -300.00K |
| Net Income | -110.56M | -134.52M | -217.66M | -224.43M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -23.35M | -11.81M | -7.35M | -10.03M | -23.13M | -20.16M | 5.27M | -8.21M | -9.22M | -4.36M | -3.78M | -2.51M | 8.55M | 2.40M | 1.90M | -700.00K | -9.40M | -9.40M | -9.80M | -9.90M | -5.60M | -4.30M | -3.90M | -4.50M | -5.00M | -3.80M |
| Net Income Ratio | -87.02% | -124.93% | -252.08% | -253.20% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,828.79% | -564.64% | -795.24% | -6,266.94% | -4,893.93% | 0.00% | -152.29% | -170.63% | -90.00% | -64.97% | -57.29% | 254.09% | 11.76% | 9.50% | -3.83% | -50.27% | -58.39% | -61.64% | -49.75% | -76.71% | -153.57% | -162.50% | -160.71% | -200.00% | -223.53% |
| EPS | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.70 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 10.40 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| EPS Diluted | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.25 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 9.60 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| Weighted Avg Shares Out | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 78.95K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.24K | 250.99K | 248.18K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
| Weighted Avg Shares Out (Dil) | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 79.49K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.43K | 253.15K | 254.76K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event...
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00...
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance ZYNRELEF® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash equivalents of $80.4 million Announced partnership with CrossLink Life Sciences,...
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Heron Therapeutics Is Out Of Survival Mode
Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help accelerate growth in 2024.
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Source: https://incomestatements.info
Category: Stock Reports